Previous close | 14.66 |
Open | 14.63 |
Bid | 14.08 x 400 |
Ask | 14.17 x 400 |
Day's range | 13.84 - 14.81 |
52-week range | 6.81 - 29.70 |
Volume | |
Avg. volume | 250,978 |
Market cap | 293.474M |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | -11.60 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 40.00 |
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ADVM Announces Q4 and Full Year 2023 Results with Strategic Clinical and Corporate Developments
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.